Rustige C, Wiedemann B
Pharmazeutische Mikrobiologie, Universität Bonn, Federal Republic of Germany.
Antimicrob Agents Chemother. 1990 Jun;34(6):1107-11. doi: 10.1128/AAC.34.6.1107.
An in vitro model simulating two-compartment pharmacokinetics was used to study the antibacterial activity of lomefloxacin after single oral doses of 200 and 400 mg. Lomefloxacin produced reliable bactericidal activity against gram-negative aerobic bacteria and staphylococci. Bacterial strains for which MICs were less than 0.5 microgram/ml were inhibited with both dosing schedules. Doubling the dose from 200 to 400 mg increased the bactericidal activity only against Pseudomonas aeruginosa. Against Enterococcus faecalis lomefloxacin showed no effect. Selection of resistant variants during the simulation of treatment was observed with Staphylococcus aureus and P. aeruginosa.
采用模拟双室药代动力学的体外模型，研究了单次口服200毫克和400毫克洛美沙星后的抗菌活性。洛美沙星对革兰氏阴性需氧菌和葡萄球菌具有可靠的杀菌活性。两种给药方案均能抑制最低抑菌浓度小于0.5微克/毫升的菌株。将剂量从200毫克加倍至400毫克仅增加了对铜绿假单胞菌的杀菌活性。洛美沙星对粪肠球菌无作用。在模拟治疗过程中，观察到金黄色葡萄球菌和铜绿假单胞菌出现了耐药变异株。
